Tags

Type your tag names separated by a space and hit enter

Microablative fractional CO2 laser for the genitourinary syndrome of menopause: power of 30 or 40 W?
Lasers Med Sci. 2017 Nov; 32(8):1865-1872.LM

Abstract

This retrospective case-control study aimed to compare 30 versus 40 W power of CO2 laser for the therapy of genitourinary syndrome of menopause (GSM). Postmenopausal women with severe intensity of dyspareunia and dryness were eligible to be included in this study. Primary outcomes were dyspareunia and dryness. Secondary outcomes were itching/burning, dysuria, frequency and urgency, Female Sexual Function Index (FSFI), vaginal maturation value (VMV), and Vaginal Health Index Score (VHIS). One laser therapy was applied every month for 3 months. Outcomes were evaluated at baseline and 1 month following the 3rd therapy. Fifty (25 per group) women were included in this study. In the 30-W group, mean improvement of dyspareunia, dryness, itching/burning, FSFI, VMV, and VHIS was 6.1 ± 1.7, 6.0 ± 1.9, 5.9 ± 2.0, 16.6 ± 6.7, 29.9 ± 13.0, and 11.0 ± 2.9, respectively (within group comparisons all p < 0.001). In the 40-W group, mean improvement of dyspareunia, dryness, itching/burning, FSFI, VMV, and VHIS was 6.1 ± 1.7, 6.5 ± 2.0, 5.2 ± 2.5, 14.8 ± 7.1, 25.0 ± 13.4, and 10.5 ± 4.1, respectively (within-group comparisons, all p ≤ 0.001). Comparison between 30 and 40 W revealed that mean improvement or presence of all GSM symptoms and clinical signs was not statistically significant different. CO2 laser therapy may improve GSM symptoms and clinical signs. This improvement did not seem to associate to power of 30 or 40 W.

Authors+Show Affiliations

Urogynecology Unit, 1st Department of Obstetrics and Gynecology, "Alexandra" Hospital, Medical School, National and Kapodistrian University of Athens, Vasilisis Sofias Ave. 80, 11528, Athens, Greece. Alfa Institute of Biomedical Sciences (AIBS), Athens, Greece.Urogynecology Unit, 1st Department of Obstetrics and Gynecology, "Alexandra" Hospital, Medical School, National and Kapodistrian University of Athens, Vasilisis Sofias Ave. 80, 11528, Athens, Greece.Alfa Institute of Biomedical Sciences (AIBS), Athens, Greece. Department of Medicine, Tufts University School of Medicine, Boston, MA, USA. Department of Medicine-Infectious Diseases, Iaso General Hospital, Athens, Greece.Cytology Department, "Alexandra Hospital", Athens, Greece.Obstetrics and Gynecology Unit, IRCCS San Raffaele Hospital, Italy Urogynecology Unit, Vita-Salute San Raffaele University, Milan, Italy.Urogynecology Unit, 1st Department of Obstetrics and Gynecology, "Alexandra" Hospital, Medical School, National and Kapodistrian University of Athens, Vasilisis Sofias Ave. 80, 11528, Athens, Greece. stavros.athanasiou@gmail.com.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

28770400

Citation

Pitsouni, Eleni, et al. "Microablative Fractional CO2 Laser for the Genitourinary Syndrome of Menopause: Power of 30 or 40 W?" Lasers in Medical Science, vol. 32, no. 8, 2017, pp. 1865-1872.
Pitsouni E, Grigoriadis T, Falagas M, et al. Microablative fractional CO2 laser for the genitourinary syndrome of menopause: power of 30 or 40 W? Lasers Med Sci. 2017;32(8):1865-1872.
Pitsouni, E., Grigoriadis, T., Falagas, M., Tsiveleka, A., Salvatore, S., & Athanasiou, S. (2017). Microablative fractional CO2 laser for the genitourinary syndrome of menopause: power of 30 or 40 W? Lasers in Medical Science, 32(8), 1865-1872. https://doi.org/10.1007/s10103-017-2293-8
Pitsouni E, et al. Microablative Fractional CO2 Laser for the Genitourinary Syndrome of Menopause: Power of 30 or 40 W. Lasers Med Sci. 2017;32(8):1865-1872. PubMed PMID: 28770400.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Microablative fractional CO2 laser for the genitourinary syndrome of menopause: power of 30 or 40 W? AU - Pitsouni,Eleni, AU - Grigoriadis,Themos, AU - Falagas,Matthew, AU - Tsiveleka,Angeliki, AU - Salvatore,Stefano, AU - Athanasiou,Stavros, Y1 - 2017/08/02/ PY - 2017/03/24/received PY - 2017/07/21/accepted PY - 2017/8/5/pubmed PY - 2018/2/6/medline PY - 2017/8/4/entrez KW - Dryness KW - Dyspareunia KW - FSFI KW - GSM KW - Laser power KW - Urgency SP - 1865 EP - 1872 JF - Lasers in medical science JO - Lasers Med Sci VL - 32 IS - 8 N2 - This retrospective case-control study aimed to compare 30 versus 40 W power of CO2 laser for the therapy of genitourinary syndrome of menopause (GSM). Postmenopausal women with severe intensity of dyspareunia and dryness were eligible to be included in this study. Primary outcomes were dyspareunia and dryness. Secondary outcomes were itching/burning, dysuria, frequency and urgency, Female Sexual Function Index (FSFI), vaginal maturation value (VMV), and Vaginal Health Index Score (VHIS). One laser therapy was applied every month for 3 months. Outcomes were evaluated at baseline and 1 month following the 3rd therapy. Fifty (25 per group) women were included in this study. In the 30-W group, mean improvement of dyspareunia, dryness, itching/burning, FSFI, VMV, and VHIS was 6.1 ± 1.7, 6.0 ± 1.9, 5.9 ± 2.0, 16.6 ± 6.7, 29.9 ± 13.0, and 11.0 ± 2.9, respectively (within group comparisons all p < 0.001). In the 40-W group, mean improvement of dyspareunia, dryness, itching/burning, FSFI, VMV, and VHIS was 6.1 ± 1.7, 6.5 ± 2.0, 5.2 ± 2.5, 14.8 ± 7.1, 25.0 ± 13.4, and 10.5 ± 4.1, respectively (within-group comparisons, all p ≤ 0.001). Comparison between 30 and 40 W revealed that mean improvement or presence of all GSM symptoms and clinical signs was not statistically significant different. CO2 laser therapy may improve GSM symptoms and clinical signs. This improvement did not seem to associate to power of 30 or 40 W. SN - 1435-604X UR - https://www.unboundmedicine.com/medline/citation/28770400/Microablative_fractional_CO2_laser_for_the_genitourinary_syndrome_of_menopause:_power_of_30_or_40_W DB - PRIME DP - Unbound Medicine ER -